The Oncology Institute, Inc. (TOI) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
The Oncology Institute, Inc. (TOI) Earnings Overview
As of June 13, 2026, The Oncology Institute, Inc. (TOI) reported trailing twelve-month net income of -$44M, reflecting +23.9% year-over-year growth. The company earned $-0.04 per diluted share over the past four quarters, with a net profit margin of -12.1%.
Looking at the long-term picture, TOI's historical earnings data spans multiple years. The company achieved its highest annual net income of $152,000 in fiscal 2022.
The Oncology Institute, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AIOT (-$32M net income, -14.1% margin), ONCO (-$10M net income, -1721.0% margin), USPH ($11M net income, 1.9% margin), TOI has outperformed on profitability metrics. Compare TOI vs AIOT →
TOI Earnings vs Peers
Earnings metrics vs comparable public companies
TOI Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$61M | +6.3% | -$36M | $-0.54 | -12.1% | -7.2% |
| 2024 | -$65M | +22.2% | -$60M | $-0.71 | -16.4% | -15.3% |
| 2023 | -$83M | -54750.0% | -$77M | $-0.92 | -25.6% | -23.8% |
| 2022 | $152,000 | +101.4% | -$82M | $-0.21 | 0.1% | -32.5% |
| 2021 | -$11M | +23.7% | -$46M | $-0.16 | -5.4% | -22.6% |
| 2020 | -$14M | -256.1% | -$8M | $-0.24 | -7.6% | -4.4% |
| 2019 | -$4M | - | -$3M | $-0.06 | -2.6% | -1.7% |
Download Data
Export TOI earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in TOI back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in TOI be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs TOI Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationTOI vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowTOI — Frequently Asked Questions
Quick answers to the most common questions about buying TOI stock.
What is TOI earnings per share (EPS)?
TOI trailing twelve-month (TTM) diluted EPS is $-0.04, reflecting +23.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is The Oncology Institute, Inc.'s net income?
The Oncology Institute, Inc. (TOI) trailing twelve-month net income is $-44M as of 2025. Earnings grew +23.9% year-over-year.
Is TOI profitable?
TOI is not currently profitable on a TTM basis, reporting a net loss of $-44M. Net margin is -12.1%. Investors should monitor for a return to profitability.
What is TOI's earnings growth rate?
TOI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are TOI's profit margins?
The Oncology Institute, Inc. net profit margin is -12.1%, operating margin is -7.2%, and gross margin is +15.2%. Below-average margins reflect competitive or cost pressures. Return on Equity is N/A.
Is TOI growing earnings?
Yes, TOI earnings are accelerating — EPS growth of +23.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-44M. Earnings momentum is strengthening.
What was TOI's best earnings year?
The Oncology Institute, Inc.'s highest annual net income on record is $152000.00, achieved in fiscal year 2022. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were TOI's earnings last quarter?
TOI's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-0.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.